Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials

Figures & data

Figure 1. Flowchart of study selection.

Figure 2. (a, b). Risk of bias of included studies.

Table 1. Summary of clinical studies included in the meta-analysis.

Study	Country	Sample size		Gender (M/F)	Mean Age (year)		Intervention		Route of dosing	Measured outcomes
		EG	CG		EG	CG	EG	CG
Glatt et al. (13) (NCT02529956)	UK	26	13	30/9	39.53	38.22	BKZ 8 mg only once BKZ 40 mg only once BKZ 160 mg only once BKZ 480 mg only once BKZ 640 mg only once	Placebo	Intravenous	TEAEs Serious TEAEs
Papp et al. (14) (NCT02905006)	Canada	BKZ 64 mg: 39 BKZ 160 mg: 43 BKZ 320 mg: 43 BKZ 480 mg:43	42	163/87	BKZ 64 mg: 44.2 BKZ 160 mg: 43.4 BKZ 320 mg: 42.6 BKZ 480 mg:42.9	46.7	BKZ 64 mg Q4W BKZ 160 mg Q4W BKZ 320 mg Q4W BKZ 480 mg Q4W	Placebo	Subcutaneous	PASI75 PASI90 PASI100 IGA response TEAEs Serious TEAEs
Glatt et al. (12) (NCT02141763)	UK	39	14	26/26	45.9	37.4	BKZ multiple doses Q3W (560/320/240/160/80 mg)	Placebo	Intravenous	PASI75 PASI100 TEAEs Serious TEAEs
Ritchlin et al. (11) (NCT02969525)	USA	BKZ 16 mg: 29 BKZ 160 mg: 28 BKZ 320 mg: 26	28	91/74	BKZ 16 mg: 50.0 BKZ 160 mg: 48.0 BKZ 320 mg: 50.4	49.0	BKZ 16 mg Q4W BKZ 160 mg Q4W BKZ 320 mg Q4W	Placebo	Subcutaneous	PASI75 PASI90 PASI100 TEAEs Serious TEAEs
Gordon et al. (15) (NCT03410992)	USA	349	86	313/122	BKZ 320 mg:44.5	43.5	BKZ 320 mg Q4W	Placebo	Subcutaneous	PASI75 PASI90 PASI100 IGA response P-SIM pain response P-SIM itch response P-SIM scaling response TEAEs Serious TEAEs
Reich et al. (16) (NCT03370133)	Germany	321	83	289/115	45.2	49.7	BKZ 320 mg Q4W	Placebo	Subcutaneous	PASI75 PASI90 PASI100 IGA response SIM pain response P-SIM itch response P-SIM scaling response TEAEs Serious TEAEs

EG: experiment group; CG: control group; BKZ: bimekizumab; IGA: Investigator’s Global Assessment; PASI: Psoriasis Area and Severity Index; Q3W: every 3 weeks; Q4W: every 4 weeks.

Figure 3. Forest plot for the proportion of patients achieving PASI75.

Figure 4. Forest plot for the proportion of patients achieving PASI90.

Figure 5. Forest plot for the proportion of patients achieving PASI100.

Figure 6. Forest plot for the proportion of patients achieving IGA response.

Figure 7. Forest plot for the proportion of patients achieving P-SIM pain response.

Figure 8. Forest plot for the proportion of patients achieving P-SIM itch response.

Figure 9. Forest plot for the proportion of patients achieving P-SIM scaling response.

Figure 10. Forest plot of the proportion of patients with any treatment-emergent adverse effects (TEAEs).

Figure 11. Forest plot of the proportion of patients with serious TEAEs.

Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001.

 PubMed Web of Science ®Google Scholar

Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277–286.e10.

 PubMed Web of Science ®Google Scholar

Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–532.

 PubMed Web of Science ®Google Scholar

Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427–440.

 PubMed Web of Science ®Google Scholar

Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486.

 PubMed Web of Science ®Google Scholar

Data availability statement

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.